Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leukemias. The diagnostic workup of patients with suspected myeloid neoplasms is labor-intensive and operationally complex requiring coordination of multiple clinical and laboratory personnel, resources and requires integration of highly fragmented results. In this presentation, we will discuss the hematopathologist’s perspective on the clinical impact of recent advancements in NGS testing.
1. Understand the contribution of genetic abnormalities in the diagnostic workup of patients with suspected myeloid neoplasms
2. Recognize the limitations of current diagnostic workflow in providing timely integrated genomic results for patients with suspected myeloid neoplasms
3. Become familiar with clinical scenarios where rapid integrated NGS may facilitate diagnostic workup of patients with suspected hematologic malignancies